Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism. We evaluated the efficacy and safety of long‐acting pasireotide during a long‐term extension study in patients with CD.

[1]  S. Webb,et al.  Morbidity of Cushing's Syndrome and Impact of Treatment. , 2018, Endocrinology and metabolism clinics of North America.

[2]  N. Tritos,et al.  Medical Therapy for Cushing's Syndrome in the Twenty-first Century. , 2018, Endocrinology and metabolism clinics of North America.

[3]  S. Webb,et al.  Quality of Life in Cushing's disease: A long term issue? , 2018, Annales d'endocrinologie.

[4]  A. Alibrandi,et al.  Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study , 2018, Endocrine.

[5]  M. Boscaro,et al.  Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. , 2018, The lancet. Diabetes & endocrinology.

[6]  G. Arnaldi,et al.  Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial , 2017, Endocrine.

[7]  P. Chanson,et al.  Cabergoline for Cushing's disease: a large retrospective multicenter study. , 2017, European journal of endocrinology.

[8]  A. Isidori,et al.  Complications of Cushing's syndrome: state of the art. , 2016, The lancet. Diabetes & endocrinology.

[9]  Jacques Young,et al.  Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease , 2015, Pituitary.

[10]  M. Korbonits,et al.  Metabolic comorbidities in Cushing's syndrome. , 2015, European journal of endocrinology.

[11]  A. Folsom,et al.  Reducing the Blood Pressure–Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control , 2015, Journal of the American Heart Association.

[12]  S. Petersenn.  How to manage pasireotide, when using as medical treatment for Cushing’s disease , 2015, Endocrine.

[13]  Julian R. E. Davis,et al.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[15]  A. Tabarin,et al.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  A. Colao,et al.  The Treatment of Cushing's Disease. , 2015, Endocrine reviews.

[17]  C. Simeoli,et al.  The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center , 2015, Endocrine.

[18]  J. Bertherat,et al.  Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial , 2014, Pituitary.

[19]  M. Fleseriu,et al.  Treatment of Cushing's disease: a mechanistic update. , 2014, The Journal of endocrinology.

[20]  J. Schopohl,et al.  Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study , 2014, Clinical endocrinology.

[21]  M. Puig-Domingo,et al.  Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up , 2014, Pituitary.

[22]  P. Chanson,et al.  Ketoconazole in Cushing's disease: is it worth a try? , 2014, The Journal of clinical endocrinology and metabolism.

[23]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[24]  L. Katznelson.  Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. , 2013, The Journal of clinical endocrinology and metabolism.

[25]  F. Gu,et al.  Effective long-term treatment of Cushing's disease with pasireotide: a case report. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[26]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[27]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[28]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[29]  M. Fleseriu,et al.  Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[30]  A. Colao,et al.  A 12-month phase 3 study of pasireotide in Cushing's disease. , 2012, The New England journal of medicine.

[31]  陈名道,et al.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement , 2008 .

[32]  L. Nieman,et al.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[34]  L. Nieman,et al.  Cushing’s Syndrome , 2019, Canadian Family Practice Guidelines.

[35]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[36]  D. McCance,et al.  Long‐term remission rates after pituitary surgery for Cushing's disease: the need for long‐term surveillance , 2005, Clinical endocrinology.

[37]  A. Klibanski,et al.  Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. , 2003, The Journal of clinical endocrinology and metabolism.